Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment

The Hedgehog (Hh) pathway, containing the Patched (PTCH) and Smoothened (SMO) multitransmembrane proteins, is the main regulator of vertebrate embryonic development. A non-canonical Hh pathway was recently observed in numerous types of solid cancers and hematological malignancies. Although acute mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Terao, Toshiki, Minami, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523210/
https://www.ncbi.nlm.nih.gov/pubmed/30987263
http://dx.doi.org/10.3390/cells8040312
_version_ 1783419281568956416
author Terao, Toshiki
Minami, Yosuke
author_facet Terao, Toshiki
Minami, Yosuke
author_sort Terao, Toshiki
collection PubMed
description The Hedgehog (Hh) pathway, containing the Patched (PTCH) and Smoothened (SMO) multitransmembrane proteins, is the main regulator of vertebrate embryonic development. A non-canonical Hh pathway was recently observed in numerous types of solid cancers and hematological malignancies. Although acute myeloid leukemia (AML) is a common and lethal myeloid malignancy, the chemotherapy for AML has not changed in the last three decades. The Hh pathway and other intracellular signaling pathways are important for the tumor cells’ cycle or therapeutic resistance of AML cells. In this article, we will review the current trends in Hh pathway inhibitors for treating AML.
format Online
Article
Text
id pubmed-6523210
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65232102019-06-03 Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment Terao, Toshiki Minami, Yosuke Cells Review The Hedgehog (Hh) pathway, containing the Patched (PTCH) and Smoothened (SMO) multitransmembrane proteins, is the main regulator of vertebrate embryonic development. A non-canonical Hh pathway was recently observed in numerous types of solid cancers and hematological malignancies. Although acute myeloid leukemia (AML) is a common and lethal myeloid malignancy, the chemotherapy for AML has not changed in the last three decades. The Hh pathway and other intracellular signaling pathways are important for the tumor cells’ cycle or therapeutic resistance of AML cells. In this article, we will review the current trends in Hh pathway inhibitors for treating AML. MDPI 2019-04-03 /pmc/articles/PMC6523210/ /pubmed/30987263 http://dx.doi.org/10.3390/cells8040312 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Terao, Toshiki
Minami, Yosuke
Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
title Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
title_full Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
title_fullStr Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
title_full_unstemmed Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
title_short Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
title_sort targeting hedgehog (hh) pathway for the acute myeloid leukemia treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523210/
https://www.ncbi.nlm.nih.gov/pubmed/30987263
http://dx.doi.org/10.3390/cells8040312
work_keys_str_mv AT teraotoshiki targetinghedgehoghhpathwayfortheacutemyeloidleukemiatreatment
AT minamiyosuke targetinghedgehoghhpathwayfortheacutemyeloidleukemiatreatment

Ejemplares similares